Compare Abeona Therapeutics Inc (ABEO) vs Braze Inc (BRZE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Braze Inc — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while Braze Inc trades at $23.8 (market cap $2.75B). The key difference: Braze Inc is far larger — about 7.4× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Braze Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | BRZE | |
|---|---|---|
Market Cap | $373.32M | $2.75B |
Sector | Health | Technology |
52-Week High | $7.23 | $36.19 |
52-Week Low | $4.17 | $15.79 |
Enterprise Value | $228.22M | $2.44B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Braze (BRZE) trades at $24.40, up 2.48% on the day, with a bullish technical outlook and strong analyst support. Revenue growth accelerated to 30% year-over-year in Q1 2027, though the company remains unprofitable with a net income margin of -15.51%. Recent news highlights AI-driven product enhancements and robust customer engagement demand, contributing to positive sentiment despite recent earnings misses relative to expectations.
The investment case hinges on sustained revenue acceleration and path to profitability, supported by a 96% buy rating from analysts and a $34.78 consensus price target. Key risks include persistent losses, competitive pressures in customer engagement software, and sensitivity to enterprise marketing budgets. Upside potential exists if AI adoption drives further growth and margin improvement.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Braze Inc
Braze Inc is a customer engagement platform that powers customer-centric interactions between consumers and brands. The company provides solutions for Retail & E-commerce, Media & Entertainment, Financial Services, and Travel & Hospitality related industries.
Read more on BRZE →
